The FDA won't appeal a decision to overturn the conviction of a salesmen who was found guilty of marketing narcolepsy drug Xyrem for treating drowsiness and chronic fatigue, two conditions for which the medicine wasn't approved. A court quashed the conviction because it said FDA regulations violated free speech in a decision that could have wide ramifications for the agency's ability to regulate off-label drug marketing.
The FDA won't appeal a decision to overturn the conviction of a salesmen who was found guilty of...
From other sites
at CNBC.com (Nov 8, 2012)
at CNBC.com (Jun 14, 2011)
at CNBC.com (May 31, 2011)
at CNBC.com (Dec 31, 1969)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs